Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer

Eishi Baba, Hiromitsu Fujishima, Hitoshi Kusaba, Taito Esaki, Hiroshi Ariyama, Ken Kato, Risa Tanaka, Kenji Mitsugi, Yoshihiro Shibata, Mine Harada, Shuji Nakano

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

The combination of 5-fluorouracil (5-FU) and cisplatin (CDDP) has been reported to be active against metastatic gastric cancer (MGC) and great synergy has been shown in vivo and in vitro when 5-FU precedes CDDP. The sequential combination of S-1 (tegafur, oxonic acid, 5-chloro-2,4-dihydroxypyridine) followed by CDDP for MGC was investigated. A phase I trial applying increasing doses of oral administration of S-1 (65-80 mg/m2) for 21 days and increasing doses of CDDP (60-80 mg/m2) on day 22 every 35 days was conducted in order to determine the maximum tolerated dose (MTD) and recommended phase II dose. Patients with metastatic or recurrent gastric cancer, no prior chemotherapy, measurable disease, ECOG performance status less than 3 and adequate organ functions were eligible for the study. Three patients were treated at each dose level with escalation based on toxicity. Fifteen patients were included and evaluated for dose-limiting toxicity (DLT) and MTD. DLT included NCICTC grade 3 anorexia and fatigue in patients treated at S-1 80 mg/m2 and CDDP 80 mg/m2 (dose level 5). The other toxicities, grade 3 or higher, included neutropenia (grade 3) and nausea/vomiting (grade 3). Non-hematological toxicities were grade 1/2 and included diarrhea, nausea and stomatitis. There was no treatment-related mortality. Therefore, the recommended dose was a combination of S-1 at 80 mg/m2 and CDDP at 70 mg/m2. This sequential administration of S-1 and CDDP every 35 days is tolerable and warrants a phase II trial. A multicenter phase II study is currently under way.

Original languageEnglish
Pages (from-to)1727-1732
Number of pages6
JournalAnticancer research
Volume29
Issue number5
Publication statusPublished - May 2009

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer'. Together they form a unique fingerprint.

Cite this